{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:31:28Z","timestamp":1784194288440,"version":"3.55.0"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:p>Objective. Receipt of highly active antiretroviral therapy is associated with a decrease in the incidence of opportunistic infections (OIs) among HIV-infected adults. The goal of Pediatric AIDS Clinical Trials Group protocol 1008 was to evaluate prospectively the incidence of serious bacterial infections (SBIs) and other OIs after discontinuation of OI and\/or Pneumocystis jiroveci pneumonia (PCP) prophylaxis among HIV-infected pediatric subjects who experienced immune reconstitution while receiving stable antiretroviral therapy.<\/jats:p>\n               <jats:p>Methods. HIV-infected children and adolescents, 2 to 21 years of age, who had received OI and\/or PCP prophylaxis for \u22656 months were enrolled if they had sustained responses (&amp;gt;16 weeks before study entry) to antiretroviral therapy, with CD4+ cell percentages of \u226520% for patients &amp;gt;6 years of age or \u226525% for patients 2 to 6 years of age. Prophylaxis was discontinued at entry. To identify whether any correlation existed between functional immune reconstitution and protection from OIs, subjects were immunized with the hepatitis A virus vaccine. The association between the humoral immune response and the likelihood of developing an OI was evaluated.<\/jats:p>\n               <jats:p>Results. A total of 235 HIV-infected subjects from 43 participating sites had a median follow-up period of 132 weeks, yielding 547 person-years of observation. Twenty SBIs were observed among 19 subjects, resulting in an incidence rate of 3.66 SBIs per 100 person-years (95% confidence interval: 2.24\u20135.66 SBIs per 100 person-years). Sixteen of the events were presumed bacterial pneumonia, with 4 proven SBIs. One participant experienced 2 separate pneumonia episodes, of presumed bacterial cause. Ten subjects who developed SBIs had baseline CD4+ cell counts of \u2265750 cells per mm3, and 15 had CD4+ cell percentages of \u226525% at the time of their SBIs. Two subjects died as a result of non\u2013SBI-related causes. There were no statistically significant differences in changes over time in CD4+ cell counts or CD4+ cell percentages between subjects who experienced primary end points and those who did not. There was no evidence that baseline protease inhibitor use, gender, race\/ethnicity, age, or CD4+ cell count or percentage affected the time to development of a SBI.<\/jats:p>\n               <jats:p>Conclusions. OI or PCP prophylaxis can be withdrawn safely for HIV-infected pediatric patients who experience CD4+ cell recovery while receiving stable antiretroviral therapy. More studies are needed to assess the association between antibody responses to neoantigens and the development of SBIs.<\/jats:p>","DOI":"10.1542\/peds.2004-1847","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T01:24:38Z","timestamp":1111022678000},"page":"e488-e494","source":"Crossref","is-referenced-by-count":33,"title":["The Rate of Serious Bacterial Infections Among HIV-Infected Children With Immune Reconstitution Who Have Discontinued Opportunistic Infection Prophylaxis"],"prefix":"10.1542","volume":"115","author":[{"given":"Sharon","family":"Nachman","sequence":"first","affiliation":[{"name":"Stony Brook University, State University of New York, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philimon","family":"Gona","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Dankner","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Weinberg","sequence":"additional","affiliation":[{"name":"University of Colorado Health Sciences Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Yogev","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gershon","sequence":"additional","affiliation":[{"name":"Columbia Presbyterian Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen","family":"Rathore","sequence":"additional","affiliation":[{"name":"University of Florida Health Science Center, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Read","sequence":"additional","affiliation":[{"name":"National Institute of Child Health and Human Development, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Elgie","sequence":"additional","affiliation":[{"name":"Frontier Science and Technology Research Foundation, Amherst, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hudgens","sequence":"additional","affiliation":[{"name":"Social and Scientific Systems, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Hughes","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"2021120819315486400_R1","doi-asserted-by":"crossref","unstructured":"Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med.\u20081990;322:161\u2013165","DOI":"10.1056\/NEJM199001183220304"},{"key":"2021120819315486400_R2","doi-asserted-by":"crossref","unstructured":"Fischl MA, Dickinson GM, LaVoie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA.\u20081988;259:1185\u20131189","DOI":"10.1001\/jama.259.8.1185"},{"key":"2021120819315486400_R3","doi-asserted-by":"crossref","unstructured":"Rigaud M, Pollack H, Leibovitz E, et al. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr.\u20081994;125:476\u2013480","DOI":"10.1016\/S0022-3476(05)83301-3"},{"key":"2021120819315486400_R4","unstructured":"Centers for Disease Control and Prevention. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Recomm Rep.\u20081995;44(RR-4):1\u2013111."},{"key":"2021120819315486400_R5","unstructured":"Centers for Disease Control and Prevention. 1997 USPHS\/IDS guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep.\u20081997;46(RR-12):1\u201346."},{"key":"2021120819315486400_R6","doi-asserted-by":"crossref","unstructured":"Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med.\u20081997;126:929\u2013938","DOI":"10.7326\/0003-4819-126-12-199706150-00001"},{"key":"2021120819315486400_R7","doi-asserted-by":"crossref","unstructured":"O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med.\u20081996;334:426\u2013431","DOI":"10.1056\/NEJM199602153340703"},{"key":"2021120819315486400_R8","doi-asserted-by":"crossref","unstructured":"Ho DD. Viral counts in HIV infection. Science.\u20081996;272:1124\u20131125","DOI":"10.1126\/science.272.5265.1124"},{"key":"2021120819315486400_R9","doi-asserted-by":"crossref","unstructured":"Sepkowitz KA. Effect of prophylaxis on the clinical manifestations of AIDS-related opportunistic infection. Clin Infect Dis.\u20081998;26:806\u2013810","DOI":"10.1086\/513920"},{"key":"2021120819315486400_R10","doi-asserted-by":"crossref","unstructured":"Schneider M, Borleffs J, Stolk R, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet.\u20081999;353:201\u2013203","DOI":"10.1016\/S0140-6736(98)07204-3"},{"key":"2021120819315486400_R11","doi-asserted-by":"crossref","unstructured":"Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med.\u20081999;340:1301\u20131306","DOI":"10.1056\/NEJM199904293401701"},{"key":"2021120819315486400_R12","unstructured":"Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002 recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep.\u20082002;51(RR-8):1\u201352"},{"key":"2021120819315486400_R13","unstructured":"Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep.\u20081992;41(RR-17):1\u201319"},{"key":"2021120819315486400_R14","doi-asserted-by":"crossref","unstructured":"Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med.\u20082001;344:168\u2013174","DOI":"10.1056\/NEJM200101183440302"},{"key":"2021120819315486400_R15","doi-asserted-by":"crossref","unstructured":"Lopez J, Miro J, Pena J, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med.\u20082001;344:159\u2013167","DOI":"10.1056\/NEJM200101183440301"},{"key":"2021120819315486400_R16","doi-asserted-by":"crossref","unstructured":"El-Sadr W, Burman W, Grant L, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med.\u20082000;342:1085\u20131087","DOI":"10.1056\/NEJM200004133421503"},{"key":"2021120819315486400_R17","doi-asserted-by":"crossref","unstructured":"Currier J, Williams P, Koletar S, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count: a randomized, double-blind, placebo-controlled trial. Ann Intern Med.\u20082000;133:493\u2013503","DOI":"10.7326\/0003-4819-133-7-200010030-00008"},{"key":"2021120819315486400_R18","unstructured":"Frontier Science and Technology Research Foundation. Appendix 40: pediatric\/maternal diagnoses. Available at: www.fstrf.org\/ACTG\/appendices\/appendix40new.pdf. Accessed February 11, 2005"},{"key":"2021120819315486400_R19","unstructured":"Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. MMWR Recomm Rep.\u20081996;45(RR-15):1\u201330"},{"key":"2021120819315486400_R20","doi-asserted-by":"crossref","unstructured":"Liang KY, Zeger SL. On the use of concordant pairs in matched case-control studies. Biometrics.\u20081988;44:1145\u20131156","DOI":"10.2307\/2531742"},{"key":"2021120819315486400_R21","doi-asserted-by":"crossref","unstructured":"Murphy TF, Hendersen FW, Clyde WA Jr, et al. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol.\u20081981;113:12\u201321","DOI":"10.1093\/oxfordjournals.aje.a113061"},{"key":"2021120819315486400_R22","doi-asserted-by":"crossref","unstructured":"Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol.\u20081993;137:977\u2013988","DOI":"10.1093\/oxfordjournals.aje.a116770"},{"key":"2021120819315486400_R23","doi-asserted-by":"crossref","unstructured":"Zangwill KM, Vadheim CM, Vannier AM, et al. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of pneumococcal conjugate vaccine efficacy trial. J Infect Dis.\u20081996;174:752\u2013759","DOI":"10.1093\/infdis\/174.4.752"},{"key":"2021120819315486400_R24","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance of the Emerging Infections Program Network, Streptococcus pneumoniae, 2003. Available at: www.cdc.gov\/ncidod\/dbmd\/abcs. Accessed February 11, 2005"},{"key":"2021120819315486400_R25","doi-asserted-by":"crossref","unstructured":"Soh CH, Oleske JM, Brady MT, et al. Long-term effects of combination therapy including protease inhibitors on CD4+ T cell recovery in HIV-1 infected children and adolescents. Lancet.\u20082003;362:2045\u20132051","DOI":"10.1016\/S0140-6736(03)15098-2"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/4\/e488\/1176520\/zpe0040500e488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/4\/e488\/1176520\/zpe0040500e488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T21:16:29Z","timestamp":1638998189000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/4\/e488\/67674\/The-Rate-of-Serious-Bacterial-Infections-Among-HIV"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,4,1]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-1847","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}